Sentences with word «myelofibrosis»

This is the first study to evaluate a T2 - weighted MRI in an experimental model of myelofibrosis with examination of potential sources of the MRI signal, researchers said.

The review by John Mascarenhas discusses established and emerging treatments for myelofibrosis related anemia.

Ruxolitinib is an option for patients with so - called primary or secondary myelofibrosis whose spleen is already enlarged (splenomegaly) or who have other disease - related symptoms.

Some patients with myelofibrosis develop leukemia.

She had suffered for several years from myelofibrosis, a blood disorder that causes fibrous tissue to replace the bone marrow.

If myelofibrosis trial results are consistent with previous observations, the healthcare behemoth will help fund larger trials in order to support New Drug Applications.

This instrument comprises myelofibrosis symptoms and aggregates them to one value (total symptom score, [TSS]-RRB-.

Stem cell transplantation is currently the only option to cure myelofibrosis.

The group was able to show that an MRI could detect a pre-fibrotic state of the disease with a clear bright signal, as well as progressive myelofibrosis.

But especially in the case of advanced myelofibrosis and systemic mastocytosis, patients may survive only for several years.

Currently, the only treatment for myelofibrosis is Incyte's Jakafi, which generated sales and royalty revenue at an annualized run rate of $ 1.01 billion based on third - quarter results.

Researchers examined more than 750 pedigrees of familial hematologic malignancies and found that the same genetic alteration may be responsible for Langerhans cell histiocytosis, acute myeloid leukemia, and primary idiopathic myelofibrosis.

Patients with myelofibrosis develop splenomegaly, hypercatabolic symptoms, and anemia.

That said however, if you have been diagnosed and been able to demonstrate that through stem cell therapy that you no longer suffer from myelofibrosis, we would be happy to «submit» your life insurance application to multiple insurance companies to see if their underwriting guidelines have changed.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

The drug ruxolitinib aims to relieve the symptoms of myelofibrosis.

In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta - thalassemia, and myelofibrosis.

The underlying reason is that Geron and partner Johnson & Johnson (NYSE: JNJ) are developing a first - in - class telomerase inhibitor called imetelstat for the rare blood disorders myelodysplastic syndromes (MDS) and myelofibrosis (MF).

Incyte's (NASDAQ: INCY) Jakafi racked up $ 1.1 billion in sales last year as the only targeted therapy for patients with myelofibrosis, but a majority of patients who take it eventually relapse.

In preliminary drug - mutation matching studies, they found that JAK1 - mutated SS cells were sensitive to JAK inhibitors, drugs that are currently approved for treatment of other hematologic cancers such as polycythemia vera and myelofibrosis.

Ruxolitinib (trade name: Jakavi) has been approved since August 2012 for the treatment of adults with myelofibrosis.

«Ruxolitinib for myelofibrosis: Indication of considerable added benefit.»

This is mainly due to the fact that typical symptoms of myelofibrosis, such as night sweats, were also recorded as «adverse events.»

Myelofibrosis is a rare disease of the bone marrow, in which the bone marrow is replaced by connective tissue.

Myelofibrosis is a slow evolving condition hallmarked by increased myeloid cells and in the case of primary myelofibrosis, with an excessive number of large bone marrow cells called megakaryocytes.

For the first time, researchers have shown that using Magnetic Resonance Imaging (MRI) can effectively identify bone marrow cancer (myelofibrosis) in an experimental model.

Myelofibrosis is a clonal hematopoietic stem cell disorder characterized by pathological myeloproliferation and aberrant cytokine production that results in progressive fibrosis, inflammation, and functional compromise of the bone marrow niche.

An Open - Label, Randomized, Phase 2 Dose - Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post - Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytopenia Myelofibrosis Previously Treated with Ruxolitinib

Background: Human myeloproliferative disorders form a range of clonal haematological malignant diseases, the main members of which are polycythaemia vera, essential thrombocythaemia, and idiopathic myelofibrosis.

A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.

Dr. Nguyen's research is focused on developing novel therapy to treat myeloproliferative neoplasms, particularly for patients with myelofibrosis and mast cell disease.

Characterization of the TGF - beta1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.

To the best of our knowledge, we are not aware of any life insurance company that will insure someone who has been diagnosed with myelofibrosis.